

SGI – Colistin Resistance in Carbapenem Resistant Isolates

RE Model for Subgroup

SGII – Colistin Resistance in Naive Isolates (SG2)

Baloch et al., 2019

Qamar et al., 2019a

Younas et al., 2019

B. Jamil et al., 2018

Luxmi and Javed, 2018

Khurshid et al., 201

Indhar et al., 2017

Rahman et al., 2016

Qadeer et al., 2016

RE Model for Subgroup

RE Model for All Studies
($\tau^2 = 0.0004$, $df = 18$, $Q = 138.88$,
 $p < .0001$; $H^2 = 7.7$, $I^2 = 87.0\%$)

Test for Subgroup Differences
 $(\tau^2 = 0.0005, df = 1, Q_M = 0.08, p = 0.7855; H^2 = 8.0, I^2 = 87.5\%)$

SGIII – Carbapenem Resistance in Naive Isolates SG2

Baloch et al., 2019

Oamar et al., 2019a

Younas et al., 2019

B. Jamil et al., 2018

Luxmi and Javed, 2018

Khurshid et al., 2011

Indhar et al., 2017

Rahman et al., 2016

Qadeer et al. 2016

Qadici et al., 2010

RE Model for All Studies

($\tau^2 = 0.0743$, $df = 8$, $Q = 308.63$, $p < .0001$; $H^2 = 38.6$, $I^2 = 97.4\%$)

RE Model for All Studies (Fig. S2)

($\tau^2 = 0.0010$, $df = 69$, $Q = 3678.83$, $p < .0001$; $H^2 = 53.3$, $I^2 = 98.1\%$)

Po	EC	1.11%	0.04	[−0.07, 0.15]
H-TCH	EC	9.10%	0.00	[−0.01, 0.02]
Po	MDR-EC	0.11%	0.96	[0.60, 1.33]
H-UTI	En	10.33%	0.00	[−0.00, 0.00]
H-SIRS	ESBL-En	7.16%	0.03	[0.00, 0.05]
H-TCH	AB	9.66%	0.00	[−0.01, 0.01]
H-Pe	Asp	9.10%	0.00	[−0.01, 0.02]
H-UTI	ESBL-EC	0.15%	0.86	[0.57, 1.16]
H-ICU	En	2.92%	0.13	[0.07, 0.19]

0.03 [-0.00, 0.07]

0.02 [-0.04, 0.09]

100.00% 0.03 [-0.00, 0.05]

Po	EC	10.31%	0.15 [−0.06, 0.37]
H-TCH	EC	10.53%	1.00 [0.80, 1.20]
Po	MDR-EC	10.51%	0.29 [0.09, 0.48]
H-UTI	En	11.82%	0.39 [0.34, 0.45]
H-SIRS	ESBL-En	11.85%	0.11 [0.06, 0.16]
H-TCH	AB	10.90%	0.98 [0.81, 1.14]
H-Pe	Asp	10.60%	0.95 [0.76, 1.14]
H-UTI	ESBL-EC	11.83%	0.03 [−0.03, 0.08]
H-ICU	En	11.64%	0.29 [0.20, 0.38]

100.00% 0.45 [0.15, 0.76]

100.00% 0.11 [0.07, 0.15]

